OBJECTIVES: To investigate the effect of polymorphisms in renin angiotensin system genes on the association between angiotensin-converting enzyme inhibitor (ACEI) exposure and global and executive cognitive function in the Health, Aging and Body Composition study. DESIGN: Cohort study. SETTING: Community. PARTICIPANTS: Three thousand seventy-five participants: mean age 73.6, 58% Caucasian, 52% female, 15% taking ACE-Is, 8 years of follow-up. MEASUREMENTS: The outcomes were longitudinal change in Executive Clock Drawing Test-1 (CLOX1), the Digit Symbol Substitution test, and the Modified Mini-Mental State Examination. The genetic polymorphisms included angiotensin-converting enzyme insertion deletion (ACEID) in the ACE gene and the M235T and 6AG polymorphisms in the angiotensinogen (AGT) gene. RESULTS: For the CLOX1 outcome, there was significant interaction between 6AG and M235T polymorphisms in the AGT gene and angiotensin-converting enzyme inhibitors (ACE-Is) in Caucasian participants (P=.01 for both polymorphisms) independent of blood pressure levels. Specifically, ACE-I exposure was protective against CLOX1 score decline in carriers of the AA genotype of the 6AG and the CC genotype of the M235T (for the ACE-I vs non-ACE-I groups, P=.01 for 6AG and P=.005 for M235T) but not the other genotypes. These associations were not significant with other cognitive tests, with ACEID, or in African Americans. CONCLUSION: ACE-Is may provide a protective effect on executive function in Caucasians with AGT gene polymorphisms known to be associated with greater renin angiotensin system activity. If confirmed in a pharmacogenetic trial, ACE-Is may be found to have additional cognitive protection in a select group of elderly individuals.
OBJECTIVES: To investigate the effect of polymorphisms in renin angiotensin system genes on the association between angiotensin-converting enzyme inhibitor (ACEI) exposure and global and executive cognitive function in the Health, Aging and Body Composition study. DESIGN: Cohort study. SETTING: Community. PARTICIPANTS: Three thousand seventy-five participants: mean age 73.6, 58% Caucasian, 52% female, 15% taking ACE-Is, 8 years of follow-up. MEASUREMENTS: The outcomes were longitudinal change in Executive Clock Drawing Test-1 (CLOX1), the Digit Symbol Substitution test, and the Modified Mini-Mental State Examination. The genetic polymorphisms included angiotensin-converting enzyme insertion deletion (ACEID) in the ACE gene and the M235T and 6AG polymorphisms in the angiotensinogen (AGT) gene. RESULTS: For the CLOX1 outcome, there was significant interaction between 6AG and M235T polymorphisms in the AGT gene and angiotensin-converting enzyme inhibitors (ACE-Is) in Caucasian participants (P=.01 for both polymorphisms) independent of blood pressure levels. Specifically, ACE-I exposure was protective against CLOX1 score decline in carriers of the AA genotype of the 6AG and the CC genotype of the M235T (for the ACE-I vs non-ACE-I groups, P=.01 for 6AG and P=.005 for M235T) but not the other genotypes. These associations were not significant with other cognitive tests, with ACEID, or in African Americans. CONCLUSION:ACE-Is may provide a protective effect on executive function in Caucasians with AGT gene polymorphisms known to be associated with greater renin angiotensin system activity. If confirmed in a pharmacogenetic trial, ACE-Is may be found to have additional cognitive protection in a select group of elderly individuals.
Authors: A Taylor; M Ezquerra; G Bagri; A Yip; L Goumidi; D Cottel; D Easton; J G Evans; J Xuereb; N J Cairns; P Amouyel; M C Chartier-Harlin; C Brayne; D C Rubinsztein Journal: Am J Med Genet Date: 2001-12-08
Authors: David Reich; Nick Patterson; Vijaya Ramesh; Philip L De Jager; Gavin J McDonald; Arti Tandon; Edwin Choy; Donglei Hu; Bani Tamraz; Ludmila Pawlikowska; Christina Wassel-Fyr; Scott Huntsman; Alicja Waliszewska; Elizabeth Rossin; Rongling Li; Melissa Garcia; Alexander Reiner; Robert Ferrell; Steve Cummings; Pui-Yan Kwok; Tamara Harris; Joseph M Zmuda; Elad Ziv Journal: Am J Hum Genet Date: 2007-03-08 Impact factor: 11.025
Authors: Hedi Schelleman; Olaf H Klungel; Jacqueline C M Witteman; Monique M B Breteler; Moygan Yazdanpanah; A H Jan Danser; Albert Hofman; Cornelia M van Duijn; Anthonius de Boer; Bruno H Ch Stricker Journal: Eur J Hum Genet Date: 2007-02-14 Impact factor: 4.246
Authors: Christophe Tzourio; Craig Anderson; Neil Chapman; Mark Woodward; Bruce Neal; Stephen MacMahon; John Chalmers Journal: Arch Intern Med Date: 2003-05-12
Authors: Ruth Peters; Nigel Beckett; Francoise Forette; Jaakko Tuomilehto; Robert Clarke; Craig Ritchie; Adam Waldman; Ivan Walton; Ruth Poulter; Shuping Ma; Marius Comsa; Lisa Burch; Astrid Fletcher; Christopher Bulpitt Journal: Lancet Neurol Date: 2008-07-07 Impact factor: 44.182
Authors: Stephen B Harrap; Christophe Tzourio; François Cambien; Odette Poirier; Segolene Raoux; John Chalmers; Neil Chapman; Samuel Colman; Solenn Leguennec; Stephen MacMahon; Bruce Neal; Takayoshi Ohkubo; Mark Woodward Journal: Hypertension Date: 2003-08-18 Impact factor: 10.190
Authors: M E Marketou; E A Zacharis; S Koukouraki; M I Stathaki; D A Arfanakis; G E Kochiadakis; G Chlouverakis; N S Karkavitsas; P E Vardas Journal: J Hum Hypertens Date: 2007-11-29 Impact factor: 3.012
Authors: Azizah J Jor'dan; Victoria N Poole; Ikechukwu Iloputaife; William Milberg; Brad Manor; Michael Esterman; Lewis A Lipsitz Journal: J Gerontol A Biol Sci Med Sci Date: 2017-11-09 Impact factor: 6.053
Authors: Charles E Evans; James S Miners; Giulia Piva; Christine L Willis; David M Heard; Emma J Kidd; Mark A Good; Patrick G Kehoe Journal: Acta Neuropathol Date: 2020-01-25 Impact factor: 15.887